Patents by Inventor Haiyang Hu
Haiyang Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11955323Abstract: The present invention provides a device for blocking plasma backflow in a process chamber to protect an air inlet structure, comprising an air inlet nozzle tightly connected to an air inlet flange. The inner cavity of the air inlet nozzle is provided with an air inlet guide body, wherein the air inlet guide body has an upper structure, a middle structure, and a lower structure, the upper, middle, and lower structures are an integrated structure, the upper, middle, and lower structures are all cylindrical, the cross-sectional diameter of the upper structure is smaller than that of the middle structure, a gas gathering area is arranged between the middle structure and the lower structure, and the middle structure and the lower structure are connected by the gas gathering area.Type: GrantFiled: February 29, 2020Date of Patent: April 9, 2024Assignee: JIANGSU LEUVEN INSTRUMENTS CO. LTDInventors: Na Li, Dongdong Hu, Xiaobo Liu, Haiyang Liu, Shiran Cheng, Song Guo, Zhihao Wu, Kaidong Xu
-
Patent number: 10683297Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: November 10, 2018Date of Patent: June 16, 2020Assignees: CALITOR SCIENCES, LLC, NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Ning Xi, Minxiong Li, Ju Peng, Xiaobo Li, Tao Zhang, Haiyang Hu, Wuhong Chen, Changlin Bai, Donghua Ke, Peng Chen
-
Publication number: 20190152977Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: November 10, 2018Publication date: May 23, 2019Applicant: Northern Industrial Area,Inventors: Ning Xi, Minxiong Li, Ju Peng, Xiaobo Li, Tao Zhang, Haiyang Hu, Wuhong Chen, Changlin Bai, Donghua Ke, Peng Chen
-
Patent number: 10266521Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: January 4, 2018Date of Patent: April 23, 2019Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 10059689Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: October 10, 2015Date of Patent: August 28, 2018Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
-
Publication number: 20180170993Abstract: The present invention belongs to the field of genetic engineering drugs, and provides a mutein MuR6S4TR of TRAIL, and a preparation method and use thereof. The N-terminal positions 2-11 of the amino acid sequence of the mutein consist of the transmembrane peptide sequence RRRRRR (R6) and the binding sequence AVPI of the apoptosis inhibitor XIAP, the positions 12-169 are the TRAIL protein peptide segment (124-281 aa), and the specific sequence is as shown in SEQ ID NO: 2.Type: ApplicationFiled: February 8, 2018Publication date: June 21, 2018Inventors: Shouchun Chen, Qi Xu, Juan Yan, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Publication number: 20180170994Abstract: The present invention belongs to the field of genetic engineering drugs, and provides a mutein MuR5S4TR of TRAIL, and a preparation method and use thereof. The N-terminal positions 2-10 of the amino acid sequence of the mutein consist of the transmembrane peptide sequence RRRRR (R5) and the binding sequence AVPI of the apoptosis inhibitor XIAP, the positions 11-169 are the TRAIL protein peptide segment (123-281 aa), and the specific sequence is as shown in SEQ ID NO: 2.Type: ApplicationFiled: February 9, 2018Publication date: June 21, 2018Inventors: Shouchun Chen, Qi Xu, Juan Yan, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Patent number: 10000541Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID NO: 2. The mutant selectively transforms the amino acid coding sequence of No. 114-119 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERGP to RRRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence, glycine into arginine on the 118th coding sequence and proline into arginine on the 119th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of six arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.Type: GrantFiled: May 10, 2017Date of Patent: June 19, 2018Assignee: CHENGDU HUACHUANG BIOTECHNOLOGY CO., LTDInventors: Shouchun Chen, Juan Yan, Qi Xu, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Patent number: 10000552Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence and glycine into arginine on the 118th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.Type: GrantFiled: May 10, 2017Date of Patent: June 19, 2018Assignee: CHENGDU HUACHUANG BIOTECHNOLOGY CO., LTDInventors: Shouchun Chen, Juan Yan, Qi Xu, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Publication number: 20180162841Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: January 4, 2018Publication date: June 14, 2018Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 9938257Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: September 7, 2016Date of Patent: April 10, 2018Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Publication number: 20170247424Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID NO: 2. The mutant selectively transforms the amino acid coding sequence of No. 114-119 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERGP to RRRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence, glycine into arginine on the 118th coding sequence and proline into arginine on the 119th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of six arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.Type: ApplicationFiled: May 10, 2017Publication date: August 31, 2017Inventors: Shouchun Chen, Juan Yan, Qi Xu, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Publication number: 20170247427Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence and glycine into arginine on the 118th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.Type: ApplicationFiled: May 10, 2017Publication date: August 31, 2017Inventors: Shouchun Chen, Juan Yan, Qi Xu, Xianzhou Huang, Lijia Wei, Haiyang Hu
-
Publication number: 20170081338Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: September 13, 2016Publication date: March 23, 2017Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Weilong Dai, Minxiong Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Xiaobo Li, Jun Liu, Tingjin Wang
-
Publication number: 20170073334Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: September 7, 2016Publication date: March 16, 2017Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 9499604Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.Type: GrantFiled: October 10, 2014Date of Patent: November 22, 2016Assignee: CHENGDU HUACHUANG BIOTECHNOLOGY CO., LTDInventors: Shouchun Chen, Juan Yan, Qi Xu, Haiyang Hu, Xianzhou Huang, Lijia Wei
-
Publication number: 20160229837Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: October 10, 2015Publication date: August 11, 2016Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
-
Patent number: 9403801Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: March 27, 2015Date of Patent: August 2, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Haiyang Hu, Weilong Dai
-
Publication number: 20160145317Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.Type: ApplicationFiled: October 10, 2014Publication date: May 26, 2016Applicant: CHENGDU HUACHUANG Biotechnology CO., LTDInventors: Shouchun CHEN, Juan YAN, Qi XU, Haiyang HU, Xianzhou HUANG, Lijia WEI
-
Publication number: 20150274704Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: March 27, 2015Publication date: October 1, 2015Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventors: Ning Xi, Minxiong Li, Haiyang Hu, Weilong Dai